Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension

Vascular Health and Risk Management

Volumn 4, Issue 6, 2008, Pages 1237-1248

  Ruilope, Luis M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Angiotensin II receptor blocker; Hypertension; Olmesartan medoxomil; hydrochlorothiazide; Thiazide diuretic

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; OLMESARTAN; PLACEBO; UNCLASSIFIED DRUG;

ADD ON THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; GOAL ATTAINMENT; HUMAN; LONG TERM CARE; MONOTHERAPY; OPTIMAL DRUG DOSE; REVIEW; UNSPECIFIED SIDE EFFECT; VERTIGO;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 60249093548     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Ball KJ, Williams PA, Stumpe KO. 2001. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens Suppl, 19:S49-56.
2. Barrios V, Boccanelli A, Ewald S, et al. 2007. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Clin Drug Investig, 27:545-8.
3. Benz JR, Black HR, Graff A, et al. 1998. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens, 12:861-6.
4. Brunner HR, Laeis P. 2003. Clinical efficacy of olmesartan medoxomil. J Hypertens Suppl, 21(Suppl 2):S43-6.
5. Campbell M, Sonkodi S, Soucek M, et al. 2001. A candesartan cilexetil/ hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy. Clin Exp Hypertens, 23:345-55.
6. Chobanian AV, Bakris GL, Black HR, et al. 2003. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA, 289:2560-72.
7. Chrysant SG, Weber MA, Wang AC, et al. 2004. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens, 17:252-9.
8. Cushman WC, Ford CE, Cutler JA, et al. 2002. Success and predictors of blood pressure control in diverse North American settings: the anti-hypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich), 4:393-404.
9. Dahlof B, Devereux RB, Kjeldsen SE, et al. 2002. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 359:995-1003.
10. Daiichi Sankyo, Data on file.
11. Daiichi Sankyo, Integrated Summary of Efficacy. Data on file.
12. Daiichi Sankyo, Integrated Summary of Safety. Data on file. de la Sierra A, Gil-extremera B, Calvo C, et al. 2004. Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/ nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients. J Hum Hypertens, 18:215-22.
13. Fabia MJ, Abdilla N, Oltra R, et al. 2007. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens, 25:1327-36.
14. Hansson L, Zanchetti AM, Carruthers SG, et al. 1998. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet, 351:1755-62.
15. Kereiakes DJ, Neutel JM, Punzi HA, et al. 2007. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am J Cardiovasc Drugs, 7:361-72.
16. Kochar M, Guthrie R, Triscari J, et al. 1999. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens, 12:797-805.
17. Lacourciere Y, Gil-Extremera B, Mueller O, et al. 2003. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Int J Clin Pract, 57:273-9.
18. Lacourciere Y, Poirier L. 2003. Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension. Am J Hypertens, 16:1036-42.
19. Lacourciere Y, Tytus R, O'Keefe D, et al. 2001. Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy. J Hum Hypertens, 15:763-70.
20. Law MR, Wald NJ, Morris JK, et al. 2003. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ, 326:1427.
21. Lewington S, Clarke R, Qizilbash N, et al. 2002. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 360:1903-13.
22. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens, 25:1105-87.
23. Neutel JM, Littlejohn TW, Chrysant SG, et al. 2005. Telmisartan/ hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension. Hypertens Res, 28:555-63.
24. Neutel JM, Smith DH, Silfani TN, et al. 2006. Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. J Hum Hypertens, 20:255-62.
25. Neutel JM, Smith DH, Weber MA, et al. 2004. Use of an olmesartan medoxomil-based treatment algorithm for hypertension control. J Clin Hypertens (Greenwich), 6:168-74.
26. O'Brien E, Asmar R, Beilin L, et al. 2003. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens, 21:821-48.
27. Pickering TG, James GD, Boddie C, et al. 1988. How common is white coat hypertension? JAMA, 259:225-8.
28. Psaty BM, Lumley T, Furberg CD, et al. 2003. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA, 289:2534-44.
29. Psaty BM, Smith NL, Siscovick DS, et al. 1997. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA, 277:739-45.
30. Puchler K, Laeis P, Stumpe KO. 2001. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens Suppl, 19:S41-8.
31. Ram CV. 2004. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens (Greenwich), 6:569-77.
32. Salerno CM, Demopoulos L, Mukherjee R, et al. 2004. Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. J Clin Hypertens (Greenwich), 6:614-20.
33. Sellin L, Stegbauer J, Laeis P, et al. 2005. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J Hypertens, 23:2083-92.
34. Stumpe KO, Ludwig M. 2002. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens, 16(Suppl 2):S24-48.
35. Waeber B, Aschwanden R, Sadecky L, et al. 2001. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. J Hypertens, 19:2097-104.
36. Watanabe LA, Wei M, Sun N, et al. 2006. Effect on blood pressure control of switching from valsartan monotherapy to losartan/hydrochlorothiazide in Asian patients with hypertension: results of a multicentre open-label trial. Curr Med Res Opin, 22:1955-64.
37. White WB, Giles T, Bakris GL, et al. 2006. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. Am Heart J, 151:176-84.
38. Whitworth JA. 2003. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens, 21:1983-92.